- Home
- REVB vs QLGN Comparison
REVB vs QLGN Comparison
Compare REVB & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- QLGN
- Stock Information
- Founded
- REVB 2020
- QLGN 1996
- Country
- REVB United States
- QLGN United States
- Employees
- REVB N/A
- QLGN N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- QLGN Health Care
- Exchange
- REVB Nasdaq
- QLGN Nasdaq
- Market Cap
- REVB 2.3M
- QLGN 2.4M
- IPO Year
- REVB N/A
- QLGN N/A
- Fundamental
- Price
- REVB $4.31
- QLGN $3.55
- Analyst Decision
- REVB
- QLGN
- Analyst Count
- REVB 0
- QLGN 0
- Target Price
- REVB N/A
- QLGN N/A
- AVG Volume (30 Days)
- REVB 175.9K
- QLGN 110.9K
- Earning Date
- REVB 03-21-2025
- QLGN 04-07-2025
- Dividend Yield
- REVB N/A
- QLGN N/A
- EPS Growth
- REVB N/A
- QLGN N/A
- EPS
- REVB N/A
- QLGN N/A
- Revenue
- REVB N/A
- QLGN N/A
- Revenue This Year
- REVB N/A
- QLGN N/A
- Revenue Next Year
- REVB N/A
- QLGN N/A
- P/E Ratio
- REVB N/A
- QLGN N/A
- Revenue Growth
- REVB N/A
- QLGN N/A
- 52 Week Low
- REVB $3.34
- QLGN $2.96
- 52 Week High
- REVB $69.44
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- REVB 40.86
- QLGN 47.06
- Support Level
- REVB $3.80
- QLGN $3.16
- Resistance Level
- REVB $4.54
- QLGN $3.75
- Average True Range (ATR)
- REVB 0.37
- QLGN 0.21
- MACD
- REVB 0.18
- QLGN 0.06
- Stochastic Oscillator
- REVB 68.13
- QLGN 67.25
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.